Generate Biomedicines Inc GENB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Generate Biomedicines to Participate in November Investor Conferences
-
Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
-
Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored’ CAR T Therapy for Ovarian Cancer
-
Generate Biomedicines Inc. to Participate in September Investor Conferences
-
Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update
Trading Information
- Previous Close Price
- $12.35
- Day Range
- $12.20–13.39
- 52-Week Range
- $11.00–22.67
- Bid/Ask
- $13.52 / $13.89
- Shares Outstanding
- 128.35M
- Market Cap
- $1.70B
- Volume/Avg
- 9,117 / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 49.64
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- —
Valuation
|
Metric
|
GENB
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.72 |
Price/Sales | 49.64 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
GENB
|
|---|---|
Quick Ratio | 8.08 |
Current Ratio | 8.30 |
Interest Coverage | −329.66 |
Quick Ratio
GENB
Profitability
|
Metric
|
GENB
|
|---|---|
Return on Assets (Normalized) | −45.62% |
Return on Equity (Normalized) | −195.08% |
Return on Invested Capital (Normalized) | −132.55% |
Return on Assets
GENB
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|Mc^h$BN | LOCK|^ZM@ | $132B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|gT@!Qk | LOCK|>%%f | $84B | |||
| Moderna Inc
MRNA
| LOCK|Nz#rcx | LOCK|q^ | $83B | |||
| argenx SE ADR
ARGX
| LOCK|@%p%&mx | LOCK|<$g | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|d!?N%&# | LOCK|K< | $42B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|Y^XtWG | LOCK|M>tD# | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|%yy^#k$ | LOCK|hR!c | $29B | |||
| Incyte Corp
INCY
| LOCK|@gmw#T | LOCK|%% | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|!?kY$@c | LOCK|%& | $22B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|pcF<JFQ | LOCK|J> | $14B |
United States